PharmNovo AB announces that the drug product for its lead candidate PN6047 has been manufactured for the upcoming Phase IIa proof-of-concept (PoC) study in neuropathic pain.PharmNovo is a ...
Scandinavian Real Heart AB (publ) announces today that the company’s artificial heart technology, its founder and inventor Dr. Azad Najar, and long-standing clinical research collaborator Professor ...
Thursday, April 9, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be ...
First patient dosed in France, expanding the DOMISOL study beyond Australia · DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development ...
Neurodiagnostics Market OverviewThe Neurodiagnostics Market is anticipated to grow at a steady rate of 7–8% between 2023 and 2028, supported by continuous innovation and rising clinical demand. The ...
Dental Practice Management Software Market OverviewThe global dental practice management software market is witnessing steady ...
The Digital Therapeutics (DTx) Market sector is undergoing rapid expansion, with forecasts indicating a compound annual ...
GOTHENBURG, SE / ACCESS Newswire / April 9, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that ...
STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical ...
Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence ---- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette ---- ...
RxERP ( a leading provider of pharmaceutical supply chain infrastructure, today announced the release of a major upgrade to its flagship serialized ERP and pharmaceutical inventory management platform ...
"As CMS Launches its $500 Cannabinoid "Engagement Incentive," MMJ International Holdings Warns of a Regulatory "Double ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results